- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02895932
Serotonin and Amyloidopathy
August 31, 2018 updated by: Roger L. Albin, University of Michigan
The purpose of this study is to determine if changes in brain serotonin affects the accumulation of amyloid in the brain.
The investigators will use brain imaging methods to measure the amount of serotonin and amyloid in the brain of individuals with Parkinson's Disease (PD) and otherwise healthy older people.
PD participants will undergo repeat brain imaging to assess amyloid accumulation two years after their first brain imaging session.
All participants will undergo examinations to assess their motor function, and asked questions to assess their mood and thinking.
Study Overview
Detailed Description
Parkinson's disease (PD) is a common problem of older people often causing significant problems with thinking and memory.
Abnormal accumulation within in the brain of a protein called amyloid is felt to contribute to impaired thinking and memory in PD.
Excessive accumulation of this protein is also involved in Alzheimer disease (AD) and may influence thinking and memory in otherwise healthy older people.
Recent evidence suggests that changes in the amount of another brain chemical, serotonin, influences the amount of amyloid accumulating in the brains of people with PD and otherwise healthy older people.
The purpose of this study is to determine if changes in brain serotonin affects the accumulation of amyloid in the brain.
The investigators use brain imaging methods to measure the amount of serotonin and amyloid in the brain of individuals with PD and otherwise healthy older people.
PD participants will undergo repeat brain imaging to assess amyloid accumulation 2 years after their first brain imaging session.
All participants will undergo examinations to assess their motor function, and asked questions to assess their mood and thinking.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Persons who have been diagnosed with Parkinson disease age 45 years and older are eligible to participate in this study.
- Healthy older individuals (ages 60-80) without neurologic problems are eligible to participate.
Exclusion Criteria:
- Individuals using some drugs cannot participate. These include anti-depressant medications, buproprion, or St. John's Wort, as well as dopamine antagonist medications.
- Women of childbearing age may not participate.
- Individuals unable to have MRI scans because of a pacemaker or metal fragments may not participate.
- Individuals with a history of stroke may not participate. People with any contraindication of PET imaging such as previous participation in research procedures involving ionizing radiation may not be eligible to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Case
Patients with diagnosed Parkinson's disease
|
Serotonin, Dopamine and Amyloid PET imaging
|
Experimental: Control
Healthy adults
|
Serotonin, Dopamine and Amyloid PET imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional brain beta amyloid levels and regional brain serotonin terminal density as measured by PET brain imaging.
Time Frame: 2 years
|
The PET imaging measures of regional brain beta amyloid levels and regional serotonin terminal density will be compared across participants to determine if there is a relationship between the regional density of serotonin terminals and the accumulation of beta amyloid.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
October 1, 2017
Study Completion (Actual)
October 1, 2017
Study Registration Dates
First Submitted
December 1, 2015
First Submitted That Met QC Criteria
September 6, 2016
First Posted (Estimate)
September 12, 2016
Study Record Updates
Last Update Posted (Actual)
September 5, 2018
Last Update Submitted That Met QC Criteria
August 31, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00094478
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
Clinical Trials on PET imaging
-
University of Wisconsin, MadisonTerminatedHead and Neck Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer | CNS Brain MetastasesUnited States
-
Stanford UniversityRecruiting
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedNon-small-cell Lung CarcinomaCanada
-
Kepler University HospitalRecruiting
-
Jules Bordet InstituteCompletedColorectal Cancer Metastatic | Early Response Evaluation | Fdg-PETBelgium
-
King's College LondonCHDI Foundation, Inc.Recruiting
-
Weill Medical College of Cornell UniversityWithdrawnHead and Neck CancerUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownNeuro-Degenerative DiseaseBelgium
-
University Hospital, CaenNational Cancer Institute, FranceCompletedCancer | Brain TumorsFrance
-
University Hospital, BordeauxCompletedMedication Overuse HeadacheFrance